Levetiracetam Tablet, Extended Release
Product Images NDC 68001-113

11 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68001-113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure-levetiracetam (0ec567ac 9f44 4b97 92af 1bb615d146fb 01)

Molecular Structure-levetiracetam (0ec567ac 9f44 4b97 92af 1bb615d146fb 01)
Chemical structure of levetiracetam, showing the molecular arrangement of atoms including the pyrrolidone ring and side chains characteristic of this active ingredient.*
FDA Label Image

Figure 1 (0ec567ac 9f44 4b97 92af 1bb615d146fb 02)

Figure 1 (0ec567ac 9f44 4b97 92af 1bb615d146fb 02)
A bar chart showing percentage of patients on the vertical axis, comparing three groups: placebo (7.4%, N=95), immediate-release levetiracetam 1000 mg/day (37.1%, N=97), and immediate-release levetiracetam 3000 mg/day (39.6%, N=101). Statistically significant differences versus placebo are indicated by asterisks on the levetiracetam groups.*
FDA Label Image

Figure 2 (0ec567ac 9f44 4b97 92af 1bb615d146fb 03)

Figure 2 (0ec567ac 9f44 4b97 92af 1bb615d146fb 03)
A bar chart comparing the percentage of patients in three groups: placebo, immediate-release levetiracetam 1000 mg/day, and immediate-release levetiracetam 2000 mg/day. The percentages shown are 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, with statistical significance markers for the levetiracetam groups versus placebo.*
FDA Label Image

Figure 3 (0ec567ac 9f44 4b97 92af 1bb615d146fb 04)

Figure 3 (0ec567ac 9f44 4b97 92af 1bb615d146fb 04)
Bar chart comparing the percentage of patients experiencing an effect between placebo and immediate-release levetiracetam 3000 mg/day. The placebo group (N=104) shows 14.4% of patients, while the levetiracetam group (N=180) shows 39.4%, marked as statistically significant versus placebo with an asterisk. The y-axis represents percentage of patients from 0% to 45%.*
FDA Label Image

Figure 4 (0ec567ac 9f44 4b97 92af 1bb615d146fb 05)

Figure 4 (0ec567ac 9f44 4b97 92af 1bb615d146fb 05)
Bar chart showing the percentage of patients responding for two groups: Placebo (N=97) at 19.6% and Immediate-release levetiracetam (N=101) at 44.6%. The chart indicates a statistically significant difference favoring the immediate-release levetiracetam group compared to placebo.*
FDA Label Image

Leve Er 500mg Rev: 01/2026 (Levetiracetam Er Tabs Usp 500mg Rev 012026)

Leve Er 500mg Rev: 01/2026 (Levetiracetam Er Tabs Usp 500mg Rev 012026)
Label for Levetiracetam Extended-Release Tablets USP 500 mg by BluePoint Laboratories. The oral tablet is film-coated and intended for once daily dosing. Package contains 60 tablets. The label includes storage instructions, manufacturer details (Lupin Limited, India), and a QR code linking to the Medication Guide.*
FDA Label Image

Levetiracetam Er Tabs 500mg 60ct With Med Guide And Qr Code (Levetiracetam Er Tabs 500mg 60 Ct)

Levetiracetam Er Tabs 500mg 60ct With Med Guide And Qr Code (Levetiracetam Er Tabs 500mg 60 Ct)
Label for Levetiracetam Extended-Release Tablets USP 500 mg, oral tablets in extended-release form. The package contains 60 tablets and is labeled for BluePoint Laboratories. Label instructions include daily dosing and pharmacist attention for medication guide dispensing. The label features a barcode and additional regulatory information.*
FDA Label Image

Levetiracetam Er Tablets 500 mg 60 Tablets Rev 03-2023 (Levetiracetam Er Tablets 500 mg 60 Tablets Rev 03 2023)

Levetiracetam Er Tablets 500 mg 60 Tablets Rev 03-2023 (Levetiracetam Er Tablets 500 mg 60 Tablets Rev 03 2023)
Label for Levetiracetam Extended-Release Tablets USP 500 mg, oral dosage form, containing 60 tablets. The label indicates once daily dosing and includes storage instructions. Manufactured by Lupin Limited for BluePoint Laboratories. NDC 68001-113-06 is visible, along with barcode and batch code information.*
FDA Label Image

Leve Er 750mg Rev: 01/2026 (Levetiracetam Er Tabs Usp 750mg Rev 012026)

Leve Er 750mg Rev: 01/2026 (Levetiracetam Er Tabs Usp 750mg Rev 012026)
Label for Levetiracetam Extended-Release Tablets USP, 750 mg strength, oral tablet form, in a count of 60 tablets. The label indicates once-daily dosing and directs pharmacists to dispense the Medication Guide. Manufactured by Lupin Limited, India, for BluePoint Laboratories. The label includes storage instructions and a QR code for the Medication Guide.*
FDA Label Image
Levetiracetam Er Tab 750mg 60ct With Med Guide Link And Qr Code (Levetiracetam Er Tabs 750mg 60 Ct)
Label for Levetiracetam Extended-Release Tablets USP 750 mg, oral dosage form by BluePoint Laboratories. The label indicates a package size of 60 tablets with a once daily dosing instruction. Includes NDC 68001-114-06 and barcode, along with dosage and storage information.*
FDA Label Image

Levetiracetam Er Tablets 750 mg 60 Tablets Rev 03-2023 (Levetiracetam Er Tablets 750 mg 60 Tablets Rev 03 2023)

Levetiracetam Er Tablets 750 mg 60 Tablets Rev 03-2023 (Levetiracetam Er Tablets 750 mg 60 Tablets Rev 03 2023)
Levetiracetam Extended-Release Tablets USP 750 mg oral tablet label by BluePoint Laboratories. The label shows the NDC 68001-114-06, quantity of 60 tablets, and indicates once daily dosing. It includes storage instructions and manufacturer details for Lupin Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.